Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session ... ZENTALIS PHARMACEUTICALSApril 10, 2021 GMT ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid tumors ZN-c3 was safe and well-tolerated Identified recommended Phase 2 dose for ZN-c3 to be 300 mg QD with continuous dosing Announces plan to start Phase 1/2 osteosarcoma trial in Q3 2021 Company to host webcast event with key opinion leaders on...
Source: apnews.com